

Symbiox Investment & Trading Co. Ltd.

221, Rabindra Sarani, 3rd Floor
Room No. 1, Kolkata - 700 007
Contact : 98302 74227
CIN : L65993WB1979PLC032012
Website : www.symbioxinvestment.com
E-mail : symbioxinvestment100@gmail.com

Date: 12th November, 2025

To,
Compliance Department
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, G - Block,
Opp. Trident Hotel, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 098

To,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata- 700 001

To,
The Bombay Stock Exchange Limited,
PJ Towers, Dalal Street
Mumbai- 400 001

Subject: Outcome of Board Meeting held on 12th November, 2025.

BSE Scrip Code: 539278 CSE Scrip Code: 029461 Symbol: SYMBIOX

Dear Sir,

We would like to inform you that the Meeting of Board of Directors of **M/s. Symbiox Investment & Trading Co Ltd** was held on **Wednesday, 12th November, 2025** at its registered office address to inter-alia transact the following matters:

1. Pursuant to **Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**, approved the Unaudited Financial Results for the quarter and half year ended on **30th September, 2025**.
2. Adopted Auditor's Limited Review Report given by Statutory Auditor of the Company for the quarter and half year ended on **30th September, 2025**.
3. No other matters was transacted at the meeting.

Kindly note that the meeting of the Board of Directors **commenced at 02:30 P.M and concluded at 04:00 P.M.**

Please take the same on your record and acknowledge the receipt of the same.

Thanking You.


Yours Faithfully,

For Symbiox Investment & Trading Co Ltd


Khushboo Pitti
Company Secretary and Compliance Officer



<p align="center">SYMBIOX INVESTMENT & TRADING CO LTD 221, RABINDRA SARANI, 3RD FLOOR, ROOM NO-1, KOLKATA -700007 CIN - 165993WB1979PLC032012 Email - symbioxinvestment100@gmail.com; Website: www.symbioxinvestment.com</p>							
<p align="center">Statement of Unaudited Financial Result for the Quarter and Half year ended 30th Sept, 2025</p>							
(Rupees in Lakh except EPS)							
	Particulars	Quarter ended			Half Year		Year ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31-03-25
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue From Operations	23.15	45.81	75.16	68.96	106.39	276.36
II	Other Income	0.00	0.19	0.00	0.19	0.00	0.43
III	Total Income (I+II)	23.15	46.00	75.16	69.15	106.39	276.79
IV	EXPENSES						
	Cost of materials consumed	-	-	-	0.00	0.00	0.00
	Purchases of Stock-in-Trade	24.19	9.48	30.72	33.67	77.96	332.12
	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	-21.06	13.80	-7.10	-7.26	-41.86	-120.68
	Employee benefits expense	6.14	4.07	3.60	10.21	7.70	15.34
	Finance costs	0.00	0.00	0.00	0.00	0.00	0.00
	Depreciation and amortization expense	0.07	0.07	0.07	0.14	0.14	0.29
	Other expenses	5.58	9.54	3.65	15.12	17.48	23.79
	Total expenses (IV)	14.92	36.96	30.94	51.88	61.42	250.86
	Profit(loss) before exceptional items and tax (I-IV)	8.23	9.04	44.22	17.27	44.97	25.93
VI	Exceptional Items	-	-	-	-	-	0.00
VII	Profit(loss) before tax (V-VI)	8.23	9.04	44.22	17.27	44.97	25.93
VIII	Tax expense:						
	(I) Current tax	2.14	2.35	11.50	4.49	11.69	6.74
	(II) Deferred tax	-	-	-	-	0.00	0.00
	Profit (Loss) for the period from continuing operations (VII-VIII)	6.09	6.69	32.72	12.78	33.28	19.19
X	Profit(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit(loss) from Discontinued operations (after tax) (X-XI)	6.09	6.69	32.72	12.78	33.28	19.19
XIII	Profit(loss) for the period (IX+XII)	6.09	6.69	32.72	12.78	33.28	19.19
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-	-	-	-	-	-



	Paid up equity share Capital (No. of Shares)	31287330	31287330	31287330	31287330	31287330	31287330
	Face Value	10.00	10.00	10.00	10.00	10.00	10.00
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.019	0.0214	0.105	0.041	0.106	0.061
	(2) Diluted	0.019	0.0214	0.105	0.041	0.106	0.061
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000
XVIII	Earnings per equity share (for discontinued & continuing operations)						
	(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000

Note:

- 1 The above Unaudited financial results were reviewed by Audit Committee and approved by the Board of Directors in their meeting held on 12th November, 2025.
- 2 The previous period figures have been regrouped wherever necessary.
- 3 The Statutory auditors of the Company have carried out a "Auditor's report" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.
- 4 The Company has adopted Indian Accounting standards (Ind AS) with effect from 01st April, 2017 and accordingly, the above results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013.
- 5 The above results for the quarter & half year ended 30th Sept., 2025 along with Auditor Report has been approved by the Board of Directors of the Company.
- 6 There are no qualification in the Audit Report issued by the Auditor.

For and behalf of Board SYMBIOX INVESTMENT & TRADING CO LTD

Place: Kolkata
Date: 12.11.2025

Samit Ray
Samit Ray
Managing Director
DIN No.08406285



SYMBIOX INVESTMENT & TRADING CO LTD
221, RABINDRA SARANI, 3RD FLOOR, ROOM NO-1, KOLKATA -700007
CIN - L65993WB1979PLC032012
Email - symbioxinvestment100@gmail.com

Un-Audited Statement of Assets and Liabilities for Company

(Rs. in Lakh)

Standalone Statement of Assets and Liabilities		As at 30th Sept 2025	As at 31st March 2025
Particulars		(Unaudited)	(Audited)
A ASSEST			
1 Non-current assets			
(a) Property, plant and equipment		1.37	1.52
(b) Capital work-in -progress		-	-
(C) Goodwill		-	-
(c) other Intangible assets		-	-
(d) Intangible assets under development		-	-
(e) Investments in subsidiary, joint ventures and associate		-	-
(f) Non- current Financial Assets		-	-
(i) Non-current Investments		-	-
(ii) Non-current Trade receivables		-	-
(iii) Non-current Loans		-	-
(iv) Other Non-current financial assets		-	-
Total non-current financial assets		1.37	1.52
(g) Deferred tax assets (net)		-	-
(h) Other non-current assets		-	-
Total non-current assets		1.37	1.52
2 Current Assets			
(a) Inventories		136.90	129.64
(b) Current financial assets		-	-
(i) Current Investments		1,385.90	1,271.43
(ii) Trade receivables		13.49	15.61
(iii) Cash and cash equivalents		26.01	22.54
(iv) Bank Balance other than cash and cabs equivalents		0.81	83.34
(v) Current Loans		1,600.89	1,645.68
(vi) Other corrent financial assets		25.46	26.83
Total current financial assets		3,189.46	3,195.07
(c) Current tax assets (net)		-	-
(d) Other current financial assets		-	-
Total Current assets		3,189.46	3,195.07
Non-current assets classified as held for sale Regulatory			
3 deferral account debit balance and related deferred tax Assets		-	-
Total Assets		3,190.83	3,196.59



B	EQUITY AND LIABILITIES		
1	EQUITY		
	Equity attributable to owner of parent	-	-
	(a) Equity share Capital	3,128.73	3,128.73
	(b) Other equity	56.44	43.66
	Total Equity attributable to owner of parent	3,185.17	3,172.39
	(c) Non controlling interest	-	-
	Total Equity	3,185.17	3,172.39
2	LIABILITIES		
	Non-current liabilities		
	(a) Non-current financial liabilities		
	(i) Borrowings	-	-
	(ii) Trade Payables	-	-
	(iii) Other non-current financial liabilities	-	-
	Total non-current liabilities	-	-
	(b) Provisions	-	-
	(c) Deferred tax liabilities (net)	-	-
	(d) Deferred government grants	-	-
	(e) Other non-current liabilities	-	-
	Total non-current liabilities	-	-
3	Current liabilities		
	(a) Current Financial liabilities		
	(i) Borrowings	-	-
	(ii) Trade paybles	-10.05	15.14
	(iii) Other current financial liabilities	-	-
	Total current financial liabilities	-10.05	15.14
	(b) Other current liabilited	4.48	2.32
	(c) provisions	11.23	6.74
	(e) Current tax liabilities (Net)	-	-
	(f) Deferred government grants	-	-
	Total current liabilities	15.71	9.06
	Liabilities directly associated with assets in disposal group		
4	classified as held for sale	-	-
	Regulatory deferral account credit balance and related deferred		
5	tax liability	-	-
	Total liabilities	5.66	24.20
	Total Equity and Liabilities	3,190.83	3,196.59

For and behalf of Board SYMBIOX INVESTMENT & TRADING CO LTD

Samit Ray

Samit Ray
Managing Director
DIN No.08406285

Place: Kolkata
Date: 12.11.2025



SYMBIOX INVESTMENT & TRADING CO LTD

L65993WB1979PLC032012

Un-Audited CASH FLOW STATEMENT FOR THE PERIOD ENDED ON 30TH SEPT., 2025


	For the year ended 30th Sept. 2025 (Rupees in lakh)	For the year ended 31st March 2025 (Rupees in lakh)
CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and after extra- ordinary items (As per profit & loss account)	17.27	25.93
Adjustments for items not included	0.14	0.29
	0.01	-
Operating Profit before working capital changes	17.42	26.22
Working capital adjustments: -		
(Increase)/ decrease in current loans and advances	44.79	497.34
(Increase)/ decrease in Inventories	-7.26	-120.68
(Increase)/ decrease in Trade receivables	2.12	-14.07
(Increase)/ decrease in current assets	1.37	-17.54
Increase/ (decrease) in Trade Payable	-25.19	-11.75
Increase/ (decrease) in current liabilities	2.16	1.77
Cash generated from operations	35.41	361.29
Direct Taxes Paid(Net of refund)	-	3.93
Net cash flow from operating activities (A)	35.41	357.36
CASH FLOW FROM INVESTING ACTIVITIES		
Proceed from sale(purchase) of investments	-114.47	-283.58
(Increase)/decrease in capital expenditure	-	-
(Increase)/decrease in fixed assets	-	-
Net cash flow from investing activities (B)	-114.47	-283.58
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of equity shares	-	-
Share Application Money received(refund)	-	-
Net cash flow from financing activities (C)	-	-
Net cash flow during the year (A + B + C)	-79.06	73.78
Add: Opening cash and cash equivalents	105.88	32.10
Closing cash and cash equivalents	26.82	105.88
Components of cash and cash equivalents		
Cash in hand	26.01	22.54
Deposit with banks in current accounts	0.81	83.34
Total cash and cash equivalents	26.82	105.88

For and behalf of Board SYMBIOX INVESTMENT & TRADING CO LTD

Samit Ray

Samit Ray
Managing Director
DIN No.08406285

Place: Kolkata
Date: 12.11.2025



Independent Auditors' Limited Review Report on quarterly unaudited standalone financial results of Symbiox Investment & Trading Co Ltd pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Review Report to
The Board of Directors,
Symbiox Investment & Trading Co. Limited
221, Rabindra Sarani, 3rd Floor
Room No. 1, Kolkata-700007.



1. We have reviewed the accompanying statement of unaudited financial results of **Symbiox Investment & Trading Co. Limited** ('the Company') for the quarter ended 30th September, 2025 (the "Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement

For S S R V & Associates
Chartered Accountants
Firm Reg. No.: 135901W



Vishnu Kant Kabra
Partner

Membership No.: 403437
Place: Mumbai
Date: 12th November, 2025
UDIN: 25403437BMIQMO9700

Symbiox Investment & Trading Co. Ltd.

221, Rabindra Sarani, 3rd Floor
Room No. 1, Kolkata - 700 007
Contact : 98302 74227
CIN : L65993WB1979PLC032012
Website : www.symbioxinvestment.com
E-mail : symbioxinvestment100@gmail.com

Date: 12th November, 2025

To,
Compliance Department
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, G - Block,
Opp. Trident Hotel, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 098

To,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata- 700 001

To,
The Bombay Stock Exchange Limited,
PJ Towers, Dalal Street
Mumbai- 400 001

Subject: Disclosure of Related Party Transactions for First Half Year ended on September 30, 2025 pursuant to Regulation 23(9) of SEBI (LODR) (Amendment) Regulations, 2018.

BSE Scrip Code: 539278 CSE Scrip Code: 029461 Symbol: SYMBIOX

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, please find herewith enclosed disclosure of Related Party Transactions for the First Half Year ended on September 30, 2025.

Please take the same on your record and acknowledge the receipt of the same.

Thanking You.

Yours Faithfully,

For Symbiox Investment & Trading Co Ltd


Khushboo Pitt
Company Secretary and Compliance Officer



Encl: as above

Disclosure under Regulation 23(9) of SEBI (LODR) (Amendment) Regulations, 2018 for the half year ended 30th September, 2025.

A. Disclosure related to KMPs of Company,

Sr. No	Name of Related Party	Nature of Relationship	Transactions	Amount (Rs.)
1.	Mrs. MINA DEVI AGARWAL	Director	Remuneration & Perquisites	NIL
2	Mr. BAPPA MITRA	Director	Remuneration & Perquisites	NIL
3	Mr. SAMIT RAY	Director	Remuneration & Perquisites	Nil
4	Mr. NITESH PODDAR	Director	Remuneration & Perquisites	Nil
5.	Mr. SWAPAN SARDAR	Director	Remuneration & Perquisites	Nil
6	Mrs. SUNITA SHOW	Director	Remuneration & Perquisites	Nil
7.	Mrs. SUNITA SHOW	Chief Financial Officer	Salary	Nil
8.	Mrs. KHUSHBOO PITTI	Company Secretary	Salary	1,56,000

B. Disclosure related to other related Parties.

Sr. No.	Name of Related Party	Nature of Relationship	Transactions	Amount
1.				

